Detection of Her-2/Neu Cep 17 Mutations at Invasive Bladder Cancer

  • Gerhard Feil
  • F. Steffen Krause
  • Andreas Zumbraegel
  • Karl-H. Bichler

Abstract

Transitional cell carcinoma (TCC) of the urinary bladder is the eighth most common cancer in Germany;1 the tumor varies greatly in its biological behavior. Of superficial TCC (Ta, Tl), up to 70% will eventually be recurrent; 10 to 15% will progress to muscle invasion (≥ T2).4 About 50% of patients with muscle-invasive bladder tumors subsequently develop metastases.34,35

Keywords

Tyrosine Adenocarcinoma Oncol DAPI Xylene 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Becker N, Wahrendorf J: Krebsatlas der Bundesrepublik Deutschland 1981–1990. Berlin: Springer-Verlag, 1997.Google Scholar
  2. 2.
    Berger CS, Sandberg AA, Todd IA, Pennington RD, Haddad FS, Hecht BK, et al: Chromosomes in kidney, ureter, and bladder cancer. Cancer Genet Cytogenet, 23:1, 1986.PubMedCrossRefGoogle Scholar
  3. 3.
    Berger CS, Lutz MD, Miles BJ, Farah RN, Weiss L, Van Dyke DL: Tumor behaviour in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. Cancer Res, 47:6800, 1987.Google Scholar
  4. 4.
    Bichler K-H, Einführung: In: K-H. Bichler et al, eds. Diagnostik und Therapie des Harnblasenkarzinoms, Reinbek: Einhorn-Presse Verlag, 9–13, 1998.Google Scholar
  5. 5.
    Bichler K-H, Wechsel HW, Lahme S, Wilbert DM, Strohmaier WL: Die Stellung der transurethralen Elektroresektion in der Behandlung des Harnblasenkarzinoms (differenzierende transurethrale Resektion). In: K-H. Bichler et al., eds. Diagnostik und Therapie des Harnblasenkarzinoms, Reinbek: Einhorn-Presse Verlag, 82–91. 1998.Google Scholar
  6. 6.
    Böcking A, Schunk K, Auffermann W: Exfoliative-cytologic diagnosis of basal-cell carcinoma with the use of DNA image cytometry. Acta Cytologica, 31:143, 1987.PubMedGoogle Scholar
  7. 7.
    Böcking A: Diagnostische DNS-Zytometrie des Urothels. In: Rathert P, Roth S, eds. Urinezytologie. Berlin: Springer Verlag, 147–170, 1995.Google Scholar
  8. 8.
    Böhm N: Einfluß der Fixierung und der Säurekonzentration auf die Feulgen-Hydrolyse bei 28°C. Histochemie, 14:201, 1968.PubMedCrossRefGoogle Scholar
  9. 9.
    Böhm N, Sprenger E, Schluter G, Sandritter W: Proportionalitätsfehler bei der Feulgen-Hydrolyse. Histochemie, 15:194, 1968.PubMedCrossRefGoogle Scholar
  10. 10.
    Coomb LM, Pigott DA, Sweeney E: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer, 63:601, 1991.CrossRefGoogle Scholar
  11. 11.
    Cremer TH, Jauch A, Ried TH, Schöck E, Lengauer CH, Cremer M, et al: Fluoreszenz-in-situ-Hybridisierung. Dt Ärzteblatt, 22:1177, 1985.Google Scholar
  12. 12.
    Feulgen R, Rosenbeck H: Mikroskopisch-chemischer Nachweis einer Nucleinsäure vom Typus der Thymonucleinsäure und die darauf beruhende elektive Färbung von Zellkulturen in mikroskopischen Präparaten. Zeitschrift für Physiologische Chemie, 135:203, 1924.CrossRefGoogle Scholar
  13. 13.
    Fisher HAG, White MD, Graber MW, Sheehan CE, Ross JS: Use of HER-2/neu gene expression to predict clinical outcome in patients with transitional cell carcinoma of the urinary bladder. J Urol, 159:165, 1998.Google Scholar
  14. 14.
    Gibas Z, Prout GR, Connolly Jr. JG, Pontes JE, Sandberg AA: Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res, 44:1257, 1984.PubMedGoogle Scholar
  15. 15.
    Graumann W: Zur Standardisierung des Schiffschen Reagens. Zt wissenschaftliche. Mikroskopie, 61:225, 1953.Google Scholar
  16. 16.
    Hermanek P, Sobin LK: UICC International Union Against Cancer. In: TMN Classification of Malignant Tumours. Berlin: Springer Verlag, 133–135, 1987.CrossRefGoogle Scholar
  17. 17.
    Hopmann AH, Poddighe PJ, Smeets AW, Moesker O, Beck JL, Vooijs GP, et al: Detection of numerical chromosome aberrations in bladder cancer by in situ hybridization. Am J Pathol, 135:1105, 1989.Google Scholar
  18. 18.
    Hopmann AH, Moesker O, Smeets AWGB, Pauwels RPE, Vooijs GP, Rameakers FC: Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res, 51:644, 1991.Google Scholar
  19. 19.
    Hurwitz E, Stancovski I, Sela M, Yarden Y: Suppression and promotion of tumor growth by monoclonal antibodies to erbB-2 differentially correlate with cellular uptake. Proc Natl Acad Aci USA, 92:3353, 1985.CrossRefGoogle Scholar
  20. 20.
    Jacobellis U, Paradisco A, Tommasi S, Ricco R, Napoli A, Catucci O, et al: HER-2/neu in bladder carcinoma. Acta Urol Ital, 13(2): 129, 1999.Google Scholar
  21. 21.
    Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufmann Jr RP, Muraca PJ, et al: Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplifikation with recurrence in prostatic adenocarcinomas. J Clin Oncol, 16:1302, 1998.PubMedGoogle Scholar
  22. 22.
    Lau JLT, Fowler JE, Ghosh L: Epidermal growth factor in the normal and neoplastic kidney and bladder. J Urol, 139:175, 1988.Google Scholar
  23. 23.
    Mahdy E, Yoshihiro S, Zech L, Wester K, Pan Y, Busch C, et al: Comparison of comparative genomic hybridisation, fluorescence in situ hybridisation and flow cytometry in urinary bladder cancer. Anticancer Res, 19:7, 1999.PubMedGoogle Scholar
  24. 24.
    Matsumura K, Kallioniemi A, Kallioniemi O, Chen L, Smith HS, Smith D, et al: Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res, 52:3474, 1992.PubMedGoogle Scholar
  25. 25.
    Mayall BH: Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res, 51:3807, 1991.PubMedGoogle Scholar
  26. 26.
    Meloni MM, Peier AM, Hadard FS, Powell IJ, Block AMW, Huben RP, et al: A new approach in the diagnosis and follow up of bladder cancer. Cancer Genet Cytogenet, 71:105, 1993.PubMedCrossRefGoogle Scholar
  27. 27.
    Neal DE, Sharpies L, Smith K, Fenelly J, Hall RR, Harris AL: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65:1619, 1990.PubMedCrossRefGoogle Scholar
  28. 28.
    Nemoto R, Nakamur I, Uchida K, Harada M: Numerical chromosome aberrations in bladder cancer detected by in situ hybridization. Br J Urol, 75:470, 1995.PubMedCrossRefGoogle Scholar
  29. 29.
    Presti JC, Reuter VE, Galan T, Fair WR, Cordon-Cardo C: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res, 51:5405, 1991.PubMedGoogle Scholar
  30. 30.
    Pycha A, Mian C, Hofbauer J, Brossner C, Haitel A, Wiener H, et al: Multifocality of transitional cell carcinoma results from genetic instability of entire transitional epithelium. Urology 53:92, 1999.PubMedCrossRefGoogle Scholar
  31. 31.
    Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS: Identification of Her-2/neu oncogene amplification by fluorescence in situ hybridisation in stage I endometrial carcinoma. Mod Pathol, 10:823, 1997.PubMedGoogle Scholar
  32. 32.
    Rubben H, Lutzeyer W, Wallace DMA: The epidemiology and etiology of bladder cancer. In: Bladder Cancer. Berlin: Springer-Verlag, 1985.Google Scholar
  33. 33.
    Sandberg AA, Berger CS: Review of chromosome studies in urological tumors: Cytogenetics and molecular genetics of bladder cancer. J Urol, 151:545, 1994.PubMedGoogle Scholar
  34. 34.
    Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldmann FM: Chromosome-9 loss detected by fluorescence on situ hybridisation in bladder cancer. Int J Cancer, 64:99, 1995.PubMedCrossRefGoogle Scholar
  35. 35.
    Schalken JA, Schalken MJ: Prognostic indicators of bladder cancer. Cur Opinon Urol, 5:272, 1995.Google Scholar
  36. 36.
    Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Proc Natl Acad SCI USA, 82:6497, 1985.PubMedCrossRefGoogle Scholar
  37. 37.
    Slamon DJ, Godolphin W, Jones LA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244:707, 1989.PubMedCrossRefGoogle Scholar
  38. 38.
    Vanni R, Peretti D, Scarpa RM, Usai E: Derivative 11 marker chromosome in bladder carcinoma. Cancer Genet Cytogenet, 164:289, 1985.CrossRefGoogle Scholar
  39. 39.
    Werner W, Junker K, Ebert W, Muller C, Schubert J: Zytogenetische Veränderungen beim Harnblasenkarzinom — Einsatz der Fluoreszenz-In-Situ-Hybridisierung (FISH). In: Bichler K-H et al., eds. Diagnostik und Therapie des Harnblasenkarzinoms. Reinbek: Einhorn-Presse Verlag, 350, 1998.Google Scholar
  40. 40.
    Wheeless LL, Reeder JE, Han MJ, O’Connell R, Frank IN, Cockett ATK, et al: Bladder irrigation specimens assayed by fluoresence in situ hybridisation to interphase nuclei. Cytometry-, 17:319, 1994.PubMedCrossRefGoogle Scholar
  41. 41.
    Yokata J, Yamamoto T, Toyoshima K: Amplification of c-erbB-2 oncogene in human adenocarcinomatas in vivo. Lancet, 1:765, 1986.CrossRefGoogle Scholar
  42. 42.
    Zhang FF, Arber DA, Wilson TG, Kawachi MH, ad Slovak ML: Toward the validation of aneusomy detection by fluorescence in situ hybridisation in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical feature predicts recurrence and defines clinical testings limitations. Clin Cancer Res, 3:2317, 1997.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Gerhard Feil
    • 1
  • F. Steffen Krause
    • 1
  • Andreas Zumbraegel
    • 1
  • Karl-H. Bichler
    • 1
  1. 1.Department of UrologyEberhard-Karls-University of TuebingenTübingenGermany

Personalised recommendations